FDA approved Pfizer-BioNTech’s XFG-adapted COMIRNATY formula for adults 65 and older and high-risk people aged 5 to 64 years.
|Slideshows|July 31, 2020
NIH Updates COVID-19 Treatment Guidance on Corticosteroids, Advance Planning
Author(s)Grace Halsey
The National Institutes of Health updated guidance on use of dexamethasone and substitutes in critically ill patients, and on ensuring surrogate decision makers are identified.
Advertisement
The National Institutes of Health (NIH) on July 30, 2020 made updates on use of corticosteroids in treatment of COVID-19 and on approaches to care of the crtically ill, including considerations for advance planning to its dynamic
Advertisement
Related to this article
A Vaccine Integrity Project review found influenza, COVID-19, and RSV immunizations continue to protect against severe illness, hospitalization, and death.
Pre-existing antibodies to common microbes predicted COVID-19 vaccine response strength in healthy and immunosuppressed adults.
FDA approved bictegravir/lenacapavir for adults with suppressed HIV-1 and no known or suspected component resistance.
FDA expands dolutegravir dispersible tablets to children with HIV-1 weighing at least 2 kg, including eligible term newborns.
The organizations challenge a presidential executive order narrowing routine childhood vaccine recommendations and urging vaccines to be given separately.
The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Approves Insulin Efsitora Alfa-Gobe for Adults With Type 2 Diabetes
2
GLP-1 RAs for Weight Management: A Primary Care Approach to Risk and Monitoring
3
Individualizing Obesity Treatment in Primary Care: An Expert Discussion
4
FDA Approves Sotatercept-csrk Label Update for Newly Diagnosed PAH
5